ArticleThe Journal of experimental medicine2022
Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue.
Article in The Journal of experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- NTM-host matched infection models for the classification of drug efficacy against rapid and slow growing nontuberculous mycobacteria species.Scientific reports · 2026Article
- Prodrug florfenicol amine is activated by intrinsic resistance to target Mycobacterium abscessus.Nature microbiology · 2025Article
- Targeting Autophagy as a Strategy for Developing New Host-Directed Therapeutics Against Nontuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2025Review
- Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally.Journal of visualized experiments : JoVE · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.Tuberculosis (Edinburgh, Scotland) · 2024Review
- Treatment for non-tuberculous mycobacteria: challenges and prospects.Frontiers in microbiology · 2024Review
- ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerantAntimicrobial agents and chemotherapy · 2023Article
- Targeted and efficient delivery of rifampicin to macrophages involved in non-tuberculous mycobacterial infectionNanoscale advances · 2023Article
- MarR-Dependent Transcriptional Regulation ofAntimicrobial agents and chemotherapy · 2023Article
- Synthesis and Characterization of Phenylalanine Amides Active againstJournal of medicinal chemistry · 2023Article
- Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.Antimicrobial agents and chemotherapy · 2023Article
- Treatment of non-tuberculosis mycobacteria skin infections.Frontiers in pharmacology · 2023Review
- Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,Frontiers in cellular and infection microbiology · 2023Article
- Loss of allosteric regulation in α-isopropylmalate synthase identified as an antimicrobial resistance mechanism.npj antimicrobials and resistance · 2023Article
- Natural Products Lysobactin and Sorangicin A ShowMicrobiology spectrum · 2022Article
- Variability ofAntibiotics (Basel, Switzerland) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Nontuberculous mycobacterial pulmonary disease (NTM-PD) is treated with multiple repurposed drugs. Chemotherapy is long and often toxic, includes parenteral drugs, and suffers from poor cure rates. There is an urgent need for more efficacious, tolerated, and oral antibiotics optimized towards the treatment of NTM-PD, adapted to the spectrum of disease. In contrast to the empty NTM pipeline, drug development for the related tuberculosis lung disease has experienced a renaissance. Here, we argue that applying lessons learned from tuberculosis will facilitate the discovery of curative oral regimens for NTM-PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.